- Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trialsElizabeth Pappadopulos
Pfizer Inc, New York, NY, USA
J Clin Psychiatry 73:e742-8. 2012..We therefore present here a comprehensive set of analyses of changes in metabolic parameters from ziprasidone clinical trials...
- Experts' recommendations for treating maladaptive aggression in youthElizabeth Pappadopulos
Center for the Advancement of Children s Mental Health, Columbia University, New York, New York, USA
J Child Adolesc Psychopharmacol 21:505-15. 2011..Increasingly, pediatricians are initiating or managing such treatments despite limited evidence on optimal diagnostic, psychosocial, and medication approaches for pediatric aggression...
- Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophreniaKeming Gao
From the Mood and Anxiety Clinic in the Mood Disorders Program of the Department of Psychiatry, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH and Pfizer Inc, New York, NY
J Clin Psychopharmacol 33:425-31. 2013....
- Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part IIElizabeth Pappadopulos
Columbia University, New York, NY, USA
J Am Acad Child Adolesc Psychiatry 42:145-61. 2003..To develop treatment recommendations for the use of antipsychotic medications for children and adolescents with serious psychiatric disorders and externalizing behavior problems...